Hims Wegovy
Last updated July 14, 2026 · Independent guide · Not medical advice
What is Hims Wegovy?
Searches for Hims Wegovy usually reflect one of two questions: can I get branded Wegovy through Hims, and how does it compare with other GLP-1 options like tirzepatide or compounded semaglutide? This page is an independent, educational guide to branded GLP-1 access through Hims, the semaglutide-versus-tirzepatide comparison, and the availability and regulatory notes that make this category unusually changeable.
A note first: this is general information, not medical advice. GLP-1 medications are powerful drugs with real risks, contraindications, and an evolving regulatory status, so any decision belongs with a licensed clinician who knows your health. For the full program overview, see our hub, Hims Weight Loss.
Wegovy is Novo Nordisk’s FDA-approved, branded semaglutide product for chronic weight management. “Hims Wegovy” is shorthand for accessing branded semaglutide (or comparable branded GLP-1s) through the Hims telehealth platform, as opposed to the compounded semaglutide the platform has also offered at times.
Does Hims offer branded Wegovy?
Hims has, at various points, offered access to branded GLP-1 options, but availability of branded semaglutide such as Wegovy has depended heavily on two moving factors: the broader regulatory landscape and the relationship between Hims & Hers and Novo Nordisk, Wegovy’s manufacturer. That relationship has at times involved branded access arrangements and at times public friction, and it has shaped what Hims could offer.
The practical upshot is that whether branded Wegovy is available to you through Hims depends on your eligibility, your state, and the timing. Because this changes, the current Hims website is the authoritative source for what is offered right now. Do not assume the offering is the same as it was a few months ago.
Wegovy vs compounded semaglutide
This distinction is central to understanding the Hims weight-loss category:
| Aspect | Wegovy (branded) | Compounded semaglutide |
|---|---|---|
| Maker | Novo Nordisk | Compounding pharmacies |
| FDA status | FDA-approved finished product | Not FDA-approved as a finished product |
| Quality review | Reviewed for safety, efficacy, quality | Not reviewed the same way |
| Availability driver | Manufacturer supply, access deals | Tied to FDA shortage designations |
| Typical positioning | Higher cost | Often marketed as more affordable |
Wegovy is a finished, FDA-approved product. Compounded semaglutide is not FDA-approved as a finished product — it is prepared by compounding pharmacies and is not reviewed by the FDA for safety, effectiveness, or manufacturing quality in the same way approved drugs are. This does not automatically make it unsafe, but it removes a layer of the usual safety net, which is a genuine consideration a clinician should discuss with you. Our Hims Weight Loss hub covers the compounding context in more depth.
Semaglutide vs tirzepatide: how do they compare?
Semaglutide and tirzepatide are the two GLP-1-based medications generating the most interest, and they differ in mechanism:
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Brand (weight) | Wegovy | Zepbound |
| Brand (diabetes) | Ozempic | Mounjaro |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 and GIP receptor agonist |
| Administration | Weekly self-injection | Weekly self-injection |
| Weight-loss data | Strong trial evidence | Some data suggests greater average loss |
The key mechanistic difference is that tirzepatide acts on two hormone pathways (GLP-1 and GIP), while semaglutide acts on one (GLP-1). Some clinical trial data suggests tirzepatide may produce greater average weight loss, though this is an average across studied populations, not a guarantee for any individual. Tolerability, cost, access, and personal response all matter, and for some people semaglutide is the better fit. Neither is universally “better”; the right choice is individual, and a clinician can help weigh it.
Is tirzepatide available through Hims?
Interest in tirzepatide has been high, and its telehealth availability — whether branded (Zepbound) or, previously, compounded — has depended on regulatory status and FDA shortage designations. Because those conditions have changed over time, what Hims offers can shift accordingly. Rather than assuming tirzepatide is available, confirm the current format, availability, and eligibility directly. As with semaglutide, any compounded tirzepatide would carry the same “not FDA-approved as a finished product” caveat.
Why GLP-1 availability keeps changing
This category is uniquely volatile, and understanding why helps you interpret conflicting information online. The availability of compounded GLP-1s was closely tied to the FDA officially listing semaglutide and tirzepatide as being in shortage. During a listed shortage, compounding pharmacies had broader latitude to prepare versions of the drug. When the FDA determined a shortage had resolved, that latitude narrowed, and compounded versions could become restricted or unavailable.
That regulatory mechanism, combined with the evolving Hims–Novo Nordisk relationship on the branded side, is what drove the widely reported shifts in the telehealth GLP-1 market. It is also why the same company’s offering can look quite different from one quarter to the next. Because GLP-1 medication is central to Hims & Hers’ growth narrative, these dynamics even feed into the company’s financial story, which our Hims Stock page discusses.
What are the side effects of Wegovy and tirzepatide?
Both medications share a broadly similar side effect profile, dominated by gastrointestinal effects:
- Nausea (very common, especially early)
- Vomiting
- Diarrhea or constipation
- Reduced appetite and early fullness
These are usually strongest when starting the medication or increasing the dose, and doses are typically titrated up gradually to improve tolerability. Both drugs also carry less common but serious risks, including pancreatitis and gallbladder issues, and specific contraindications related to certain thyroid tumors and personal or family history. Individual tolerability differs, and there are questions about muscle loss and nutrition during rapid weight loss that a clinician can help manage. The “not medical advice” caveat is sincere here — these risks warrant a real clinical conversation.
How to think about Hims Wegovy and tirzepatide
If you specifically want an FDA-approved finished product, branded Wegovy (or Zepbound for tirzepatide) is the relevant option, subject to availability and cost. If affordability is the priority and you understand the trade-offs, compounded options have sometimes been positioned as cheaper — but with the important caveat that they are not FDA-reviewed and their availability can change with regulation.
We avoid quoting exact prices because they vary by product and plan and change over time, and branded GLP-1s can be expensive without insurance coverage, which frequently does not apply to weight-loss use. Compare the full monthly cost and confirm current availability directly.
What to confirm before choosing
Because this category changes so quickly, a few checks are worth making before you commit to any branded or compounded GLP-1:
- Exactly what you are getting — branded (Wegovy or Zepbound) or compounded, which active ingredient, and at what dose.
- Regulatory status of a compounded product, and what would happen to your supply if the rules shift again.
- The full cost over the months you might realistically stay on the medication, not just the first month.
- Insurance — whether any coverage applies, since it frequently does not for weight-loss use but is worth checking.
- Monitoring and support — how progress and side effects are tracked, and how you reach a clinician.
Getting clear answers here helps you avoid the disruptions and surprises that have frustrated some users when availability or pricing changed.
Making sense of a fast-moving market
The takeaway is that “Hims Wegovy” is less a fixed product than a snapshot of a category in motion. Branded semaglutide and tirzepatide are FDA-approved and well studied; compounded versions have offered lower cost but come with regulatory uncertainty and no FDA finished-product review. Which is available, and at what price, depends on manufacturer relationships and FDA shortage decisions that can change within months. That does not mean you should avoid the category — for many people GLP-1 medication has been genuinely effective — but it does mean confirming current specifics directly and not relying on older information you find online.
For related reading, see the Hims Weight Loss hub, Hims Weight Loss Reviews for user experiences, the broader Hims Reviews hub, and Hims Stock for the business angle. And because eligibility, safety, and the right medication depend on your individual health, make the final decision with a licensed clinician.